Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV: Erratum
Y. Joseph Hwang(Johns Hopkins University), Anthony T. Fojo(Johns Hopkins University), Catherine R. Lesko(Johns Hopkins University), Lauren C. Zalla(Johns Hopkins University), Jarratt D. Pytell(Kaiser Permanente), LaQuita N. Snow(National Institutes of Health), Todd T. Brown(Johns Hopkins University), Jeanne Keruly(Johns Hopkins University), Richard D. Moore(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Joyce Jones(Johns Hopkins University), G. Caleb Alexander(Johns Hopkins University)
Cited by 0
Related Papers
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
|The Journal of Infectious Diseases|1987|1.1k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694